Relevance of Solid-state Properties for Pharmaceutical Products

Polymorphism: in the Pharmaceutical Industry

Volumn , Issue , 2006, Pages 1-19

  Hilfiker, Rolf ^a   Blatter, Fritz ^a   Raumer, Markus von ^a  

^a SOLVIAS AG   (Switzerland)

Author keywords

Bioavailability of solids; Drug development; Drug discovery; Life cycle management; Pharmaceutical industry; Pharmaceutical products; Polymorphism; Solid state properties

Indexed keywords

EID: 84890682089     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/3527607889.ch1     Document Type: Chapter

References (71)

1. Ostwald, W., Z. Phys. Chem., 22 (1897) 289-330.
2. McCrone, W. C., Phys. Chem. Org. Solid State, 2 (1965) 725-767.
3. Brittain, H.G., Polymorphism in Pharmaceutical Solids, Marcel Dekker, Inc., New York (1999).
4. Byrn, S. R., Pfeiffer, R., Stowell, J. G., Solid State Chemistry of Drugs, 2nd edn., SSCI Inc., West Lafayette (1999).
5. Bernstein, J. Polymorphism in Molecular Crystals, Oxford Science Publications, Oxford (2002).
6. Datta, S., Grant, D.J.W., Nat. Rev., 3 (2004) 42-57.
7. Morris, K. R. in Polymorphism in Pharmaceutical Solids (ed. Brittain, H.G.), Marcel Dekker, New York (1999) pp. 125-181.
8. Wunderlich, B., Grebowicz, J., Adv. Polym. Sci., 60/61 (1984) 1-59.
9. Wunderlich, B., Thermochim. Acta, 340 (1999) 37-52.
10. Vadas, E. B., Toma, P., Zografi, G., Pharm. Res., 8 (1991) 148-155.
11. Morris, K. R., Newman, A.W., Bugay, D.E., Ranadive, S. A., Singh, A. K., Szyper, M., Varia, S. A., Brittain, H.G., Serajuddin, A.T. M., Int. J. Pharm., 108 (1994) 195-206.
12. Stevenson, C. L., Bennett, D. B., Lechuga- Ballesteros, D., J. Pharm. Sci., 94 (2005) 1861-1880.
13. Lipinski, C. A., Lombarda, F., Dominy, B.W., Feeney, P. J., Adv. Drug. Deliv. Rev., 46 (2001) 3-26.
14. Griesser, Ulrich J., Stowell, J. G. in Pharmaceutical Analysis, (eds. Lee, David C., Webb, Michael L.), Blackwell Publishing Ltd., Oxford (2003).
15. Henck, J.-O., Griesser, U. J., Burger, A., Pharm. Ind., 59 (1997) 165-169.
16. Stahly, G. P., at the American Chemical Society ProSpectives Polymorphism in Crystals: Fundamentals, Predictions and Industrial Practice, Tampa, FL, Feb 23-26 (2003).
17. Storey, R., Docherty, R., Higginson, P., Dallman, C., Gilmore, C., Barr, G., Dong, W., Crystallogr. Rev., 10 (2004) 45-56.
18. Stahl, P. H., Wermuth, C.G. (eds.), Handbook of Pharmaceutical Salts: Properties, Selection, and Use, Wiley-VCH, Weinheim (2002).
19. DeCamp, W. H., Am. Pharm. Rev., 4 (2001) 70-77.
20. Amidon, G. L., Lennernas, H., Shah, V. P., Crison, J. R., Pharm. Res., 12 (1995) 413-420.
21. Harman, R. J., Pharm. J., 262 (1999) 334-337.
22. Stenberg, P., Bergström, C. A. S., Luthman, K., Artursson, P., Clin. Pharmacokinet., 41 (2002) 877-899.
23. McGovern, S. L., Caselli, E., Grigorieff, N., Shoichet, B. K., J. Med. Chem., 45 (2002) 1712-1722.
24. Ren, S., Lien, E. J., in Progress in Drug Research, Vol. 54, (ed. Jucker, E.), Birkhäuser Verlag, Basel (2000) pp. 1-23.
25. Kansy, M., Senner, F., Gubernator, K., J. Med. Chem., 41 (1998) 1007-1010.
26. Irvine, J. D., Takahashi, L., Lockhart, K., Cheong, J., Tolan, J.W., Selick, H.E., Grove, J. R., J. Pharm. Sci., 88 (1999) 28-33.
27. Lipinski, C. A., Adv. Drug. Deliv. Rev., 23 (1997) 3-25.
28. Yu, L. X., Amidon, G. L., Polli, J. E., Zhao, H., Mehta, M., Conner, D. P., Shah, V. P., Lesko, L. J., Chen, M.-L., Lee, V.H.L., Hussain, A. S., Pharm. Res., 19 (2002) 921-925.
29. Johnson, K., Swindell, A., Pharm. Res., 13 (1996) 1795-1798.
30. Curatolo, W., Pharm. Sci. Technol. Today, 1 (1998) 387-393.
31. Singhal, D., Curatolo, W., Adv. Drug Deliv. Rev., 56 (2004) 335-347.
32. Artursson, P., J. Pharm. Sci., 79 (1990) 476-482.
33. Crison, J. R., in Water-Insoluble Drug Formulation (ed. Liu, R.), CRC Press, Boca Raton, FL (2000), 97-110.
34. Martinez, M.N., Amidon, G. L., J. Clin. Pharmacol., 42 (2002) 620-643.
35. Balbach, S., Korn, C., Int. J. Pharmaceutics, 275 (2004) 1-12.
36. http://www.cfsan.fda.gov/~dms/ opa-noti.html.
37. Pudipeddi, M., Serajuddin, A.T.M., J. Pharm. Sci., 94 (2005) 929-939.
38. Chemburkar, S.R, Bauer, J., Deming, K., Spiwek, H., Patel, K., Morris, J., Henry, R., Spanton, S., Dziki, W., Porter, W., Quick, J., Bauer, P., Donaubauer, J., Narayanan, B. A., Soldani, M., Riley, D., McFarland, K., Org. Process Res. Dev., 4 (2000) 413-417.
39. Löbenberg, R., Amidon, G. L., Eur. J. Pharm. Biopharm., 50 (2000) 3-12.
40. Clas, S.-D., Cotton, M., Moran, E., Spagnoli, S., Zografi, G., Vadas, E. B., Thermochim. Acta, 288 (1996) 83-96.
41. Huang, L.-F., Tong, W.-Q., Adv. Drug Deliv. Rev., 56 (2004) 321-334.
42. Giron, D., Mutz, M., Garnier, S., J. Therm. Anal. Cal. 77 (2004) 709-747.
43. Imaizumi, H., Nambu, N., Nagai, T., Chem. Pharm. Bull., 31 (1983) 2510- 2512.
44. Miyazaki, T., Yoshioka, S., Aso, Y., Kojima, S., J. Pharm. Sci., 93 (2004) 2710-2717.
45. Nichols, G., Frampton, C. S., J. Pharm. Sci., 87 (1998) 684-693.
46. Snider, D. A., Addicks, W., Owens, W., Adv. Drug Deliv. Rev., 56 (2004) 391-395.
47. Gu, C.-H., Chatterjee, K., Young Jr., V., Grant, D.J.W., J. Crystal Growth, 235 (2002) 471-481.
48. Bauer, J., Spanton, R., Henry, R., Quick, J., Dziki, W., Porter, W., Morris, J., Pharm. Res., 18 (2001) 859-866.
49. Laird, T., Org. Process Res. Dev., 8 (2004) 301-302.
50. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonised Tripartite Guideline, Impurities: Guideline for Residual Solvents, Q3C (www.ich.org).
51. Stoica, C., Verwe, P., Meekes, H., van Hoof, P. J. C. M., Kaspersen, F. M., Vlieg, E., Crystal Growth Design, 4 (2004) 765- 768.
52. Marti, E., J. Therm. Anal. Cal., 33 (1988) 37-45.
53. Giron, D., Eng. Life Sci., 3 (2003) 103- 112.
54. Hulliger, J., Angew. Chem., Int. Ed. Engl., 33 (1994) 143-162.
55. Beckmann, W., Nickisch, K., Budde, U., Org. Process Res. Dev., 5 (1998) 298-304.
56. Beckmann, W., Org. Process Res. Dev., 4 (2000) 372-383.
57. Beckmann, W., Otto, W., Budde, U., Org. Process Res. Dev., 5 (2001) 387-392.
58. Myerson, A. S. (ed.), Handbook of Industrial Crystallization, Butterworth-Heinemann, Woburn, MA (2002).
59. Heffels, S. K., Kind, M., 14th International Symposium on Industrial Crystallization, Institution of Chemical Engineers, Rugby (UK), (1999) 2234-2246.
60. Dennehy, R. D., Org. Process Res. Dev., 7 (2003) 1002-1006.
61. Trask, A.V., Shan, N., Motherwell, W. D.S., Jones, W., Feng, S., Tan, R. B. H., Carpenter, K. J., Chem. Commun., (2005) 880-882.
62. Yu, L. X., Lionberger, R. A., Raw, A. S., D'Costa, R., Wu, H., Hussain, A.S., Adv. Drug Delivery Rev., 56 (2004) 349-369.
63. Birch, M., Fussell, S. J., Higginson, P. D., McDowall, N., Marziano, I., Org. Process Res. Dev., 9 (2005) 360-364.
64. Giron, D., J. Therm. Anal. Cal., 68 (2002) 335-357.
65. Byrn, S., Pfeiffer, R., Ganey, M., Hoiberg, C., Poochikan, G., Pharm. Res., 12 (1995) 945-954.
66. Himuro, I., Tsuda, Y., Sekiguchi, K., Horikoshi, I., Kanke, M., Chem. Pharm. Bull., 19 (1971) 1034-1040.
67. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonised Tripartite Guideline, Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances: Q6A (www.ich.org).
68. Yu, L., Reutzel, S. M., Stephenson, G. A., Pharmaceutical Sci. Technol. Today, 1 (1998) 118-127.
69. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonised Tripartite Guideline, Text on Validation of Analytical Procedures: Q2A (www.ich.org).
70. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonised Tripartite Guideline, Validation on Analytical Procedures: Methology: Q2B (www.ich.org).
71. Foraita, H.-G. in Handbook of Pharmaceutical Salts: Properties, Selection, and Use (eds. Stahl, P. H., Wermuth, C. G.), Wiley-VCH, Weinheim (2002) pp. 221- 235.